Product Pipeline

Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
Ryplazim®
Congenital Deficiency (BLA filed)
Fezagepras (PBI-4050)
Additional Multiple Ascending Dose (MAD) Study
Fezagepras (PBI-4050)
Planned phase 2 study in IPF
Fezagepras (PBI-4050)
Planned Phase 1b/2a mechanistic study in patients with high triglycerides
Selective GPR84 Antagonist
Fibrosis
Selective OXER1 Antagonist
Respiratory/GI